ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $698.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +20 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $1.60B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$166.3M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $5.00M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.80M
- Shares sold short
- Change
- −1.01M
- −14.8% vs. previous
- Days to cover
- 3.43
- At average daily volume
Superinvestors holding AVBP, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding ArriVent BioPharma, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
16.4%
ArriVent BioPharma, Inc.'s share of the portfolio
- Shares
- 3,929,117
- Value
- $136.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by ArriVent BioPharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 (view filing)4:05 PM ET | Dec 10, 2025 | 55 daysLate | Hillhouse Investment Management, Ltd. and 1 other10% Owner | SSale | −555.6K | $23.37 | −$13.0M | −12.4%3.93M after | |
| Feb 1, 2024 (view filing)4:47 PM ET | Jan 30 | 2 days | Hillhouse Investment Management, Ltd. and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +14.1%4.48M after | |
| Jan 31, 2024 (view filing)4:12 PM ET | Jan 30 | 1 day | OrbiMed Advisors LLC and 3 othersDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lotsDuplicate filing |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Gordon Carl LDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lots |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Healy JamesDirector | PPurchase | +444.4K | $18.00 | +$8.00M | +35.5%1.70M after |
Top 10 13F holders, Q2 2026
See all 157 holdersThe largest institutional positions in ArriVent BioPharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4,515,531 | $156.9M | 3.30% | +114,448+2.6% | Added |
| Infinitum Asset Management, LLC | 4,438,384 | $154.2M | 15.68% | +289,461+7.0% | Added |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 3,929,117 | $136.5M | 16.40% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,250,396 | $112.9M | 0.00% | +720,095+28.5% | Added |
| OrbiMed Advisors LLC | 3,027,328 | $105.2M | 1.99% | 00.0% | Unchanged |
| FMR LLC | 2,778,959 | $96.5M | 0.00% | −237,173−7.9% | Reduced |
| Octagon Capital Advisors LP | 1,971,054 | $68.5M | 6.28% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,774,873 | $61.7M | 0.00% | +245,980+16.1% | Added |
| Sofinnova Investments, Inc. | 1,696,752 | $58.9M | 3.15% | 00.0% | Unchanged |
| State Street Corp | 1,692,986 | $58.8M | 0.00% | +271,571+19.1% | Added |
Holders of 5% or more of AVBP
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of ArriVent BioPharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Infinitum Asset Management, LLC | 13G/A | 9.90%4.12M shares | 0.00 ppfrom 9.90% | May 15, 20253 filings | Feb 17, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 9.90%3.41M shares | – | Dec 4, 20242 filings | Aug 13, 2025 | SEC |
| Hillhouse Investment Management, Ltd. | 13G/A | 9.50%3.93M shares | – | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.80%3.18M shares | +1.20 ppfrom 5.60% | Oct 24, 20245 filings | Jul 27, 2026 | SEC |
| OrbiMed Advisors LLC | 13D/A | 5.80%2.88M shares | −1.70 ppfrom 7.50% | Feb 5, 20243 filings | Oct 8, 2026 | SEC |